@prefix this: <http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo> .
@prefix sub: <http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#> .
@prefix schema: <https://schema.org/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix nt: <https://w3id.org/np/o/ntemplate/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix bl: <https://w3id.org/biolink/vocab/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .
sub:Head {
   this: np:hasAssertion sub:assertion ;
    np:hasProvenance sub:provenance ;
    np:hasPublicationInfo sub:pubinfo ;
    a np:Nanopublication .
}
sub:assertion {
   <http://purl.obolibrary.org/obo/DOID_9538> bl:category bl:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_9538> ;
    rdf:predicate bl:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB06603> ;
    a rdf:Statement ;
    rdfs:label "farydak a histone deacetylase inhibitor in combination with bortezomib and dexamethasone is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior regimens including bortezomib and an immunomodulatory agent this indication is approved under accelerated approval based on progression free survival see clinical studies 14 1 farydak a histone deacetylase inhibitor in combination with bortezomib and dexamethasone is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior regimens including bortezomib and an immunomodulatory agent this indication is approved under accelerated approval based on progression free survival continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials 1" ;
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    bl:provided_by <https://w3id.org/um/NeuroDKG> ;
    bl:relation schema:TreatmentIndication .
  <https://identifiers.org/drugbank:DB06603> bl:category bl:Drug .
}
sub:provenance {
   sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}
sub:pubinfo {
   sub:sig npx:hasAlgorithm "RSA" ;
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" ;
    npx:hasSignature "ejkgAdelRbCwcop+mYWEroyL/NoOAY7gyM1L+ZFCVYs6Rwd0q3O9FNXnkpo3VVcRMm27MPR1G6sunrxvFiJiW+Uf8lA/2E69+oJ5H/TwEFQig80kKP4b0asdnp+L7gJIeO7UZwJLfhJjLHonTahakeB63rj8bPjvaEonSWoXJpM=" ;
    npx:hasSignatureTarget this: .
  this: dct:created "2021-06-12T13:26:08.716+02:00"^^xsd:dateTime ;
    dct:creator orcid:0000-0002-1468-3557 ;
    nt:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM> ;
    nt:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM> ;
    nt:wasCreatedFromTemplate <http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs> .
}